We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Lowering Weight in Severe Obesity by Embolization of the Gastric Artery Trial (LOSEIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03185949
Recruitment Status : Completed
First Posted : June 14, 2017
Results First Posted : September 28, 2022
Last Update Posted : September 28, 2022
Sponsor:
Collaborators:
OB KLINIKA a.s. Pod Krejcárkem 975 Praha 3 - Žižkov Tel.: +420 255 725 110
Na Homolce Hospital
High Tech Med Consult Frimlova 1322/4e 15500 Prague 5 Czech Republic
Information provided by (Responsible Party):
Endobar Solutions LLC

Brief Summary:

To evaluate the efficacy and safety of the Endobar gastric embolization system for the treatment of obesity before continuing to a larger Pivotal Trial.

Investigational Device The investigational device in this clinical study is the Endobar Infusion Catheter System - a disposable system consisting of an occlusion balloon catheter, a Smart Manifold delivery system.

Study Design/Planned Number of Subjects This study is a prospective, sham controlled, single-blind 12-month trial with 1:1 randomization. A maximum of 40 subjects (obese men and women who have a body mass index (BMI) of 35.0-50.0 kg/m2) will be enrolled in the study. Eligible subjects will be randomized to treatment with Endobar Therapy (n = 20) or sham procedure control (n = 20). Endobar Therapy involves catheter-based embolization of the left gastric artery. All subjects in both Endobar Therapy and Sham Control groups will receive Lifestyle Therapy (behavioral and diet education). At the end of 6 months all subjects randomized to the Sham Control group will receive catheter-based embolization of the left gastric artery. Both Endobar Therapy and Sham Control crossover to Endobar Therapy groups will be followed for a total of 12 months.

Study Duration The duration of the study is expected to last approximately 18 months from the first enrollment . An additional 12 months to the study closeout after the last follow-up.


Condition or disease Intervention/treatment Phase
Obesity, Morbid Device: Endobar Infusion Catheter System Behavioral: Behavioral therapy Not Applicable

Detailed Description:

STUDY OBJECTIVES Objective The objective of this study is to conduct a sham controlled randomized trial to evaluate the efficacy and safety of the Endobar System for the treatment of obesity. Efficacy, Safety, and secondary outcomes will be evaluated at 6 and 12 months to allow expansion of the investigation into a larger, pivotal clinical study.

Study Design This is a prospective randomized, single blind, active treatment and sham controlled, single-center trial . After the informed consent and screening process are completed, all subjects who are eligible and wish to participate in the study will undergo baseline testing. Those who complete baseline testing will be randomized to either Endobar Therapy (ET) or Sham Treatment (ST) for 52 weeks. Both groups will be given lifestyle therapy for weight loss, which involves treatment with a behavioral education weight loss program delivered as 19 individual sessions in person over 52 weeks. Endobar Therapy involves catheter-based embolization of the left gastric artery. After 26 weeks, the ET group will continue to be monitored for an addition 26 weeks and the ST subjects will be given ET and monitored for 26 weeks. The duration of the entire study will be 52 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: This study is a prospective, sham controlled, single-blind 12-month trial with 1:1 randomization. A maximum of 40 subjects (obese men and women who have a body mass index (BMI) of 35.0-50.0 kg/m2) will be enrolled in the study. Eligible subjects will be randomized to treatment with Endobar Therapy (n = 20) or sham procedure control (n = 20). Endobar Therapy involves catheter-based embolization of the left gastric artery. All subjects in both Endobar Therapy and Sham Control groups will receive Lifestyle Therapy (behavioral and diet education). At the end of 6 months all subjects randomized to the Sham Control group will receive catheter-based embolization of the left gastric artery. Both Endobar Therapy and Sham Control crossover to Endobar Therapy groups will be followed for a total of 12 months
Masking: Double (Participant, Outcomes Assessor)
Masking Description:
  • Interventional Group: These subjects will undergo catheter-based embolization.
  • Sham Control Group: These subjects will not undergo femoral artery catheterization. Instead, lidocaine will be injected subcutaneously at the femoral artery site in the Sham Control group. Since all patients will have received at least sedation, they will not be aware of what has been done, and thus be blind to their treatment assignment
Primary Purpose: Treatment
Official Title: Efficacy and Safety of EndoBar Bariatric Embolization for Weight Management in People With Obesity
Actual Study Start Date : February 8, 2017
Actual Primary Completion Date : December 1, 2018
Actual Study Completion Date : December 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Sham Comparator: Sedation and subcutaneous lidocaine
Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
Device: Endobar Infusion Catheter System
Bariatric embolization with microspheres using Endobar Infusion Catheter System

Behavioral: Behavioral therapy
Healthy diet and exercise

Experimental: interventional: bariatric embolization
• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
Device: Endobar Infusion Catheter System
Bariatric embolization with microspheres using Endobar Infusion Catheter System

Behavioral: Behavioral therapy
Healthy diet and exercise




Primary Outcome Measures :
  1. Weight Loss [ Time Frame: 1) 6 months post-procedure/sham and 2) 12 months post-procedure ]
    1. Difference in percent total body weight (% TBWL) loss at 6 months between the Sham Control and Endobar Therapy groups. This is calculated as the difference in body weight from baseline to 6 months, relative to the baseline weight (i.e, initial weight - 6 month weight / initial weight) x 100%). The mean (i.e., average) total body weight loss of both groups was compared to assess whether there was a meaningful difference.
    2. Percent total body weight loss (%TBWL) at 12 months in the group randomized to the initial Endobar Therapy alone. This is calculated as the difference in body weight from baseline to 12 months, relative to the baseline weight (i.e, initial weight - 12 month weight / initial weight) x 100%).

  2. Number of Patients With Adverse Events [ Time Frame: 12 months post-randomization ]
    The Incidence of device-, procedure- and therapy-related adverse events up to 12 months post-procedure.

  3. Absolute Weight Loss (kg) [ Time Frame: 6 months post-procedure/sham and 12 months post-procedure ]

    6-month change: The absolute difference in the initial and 6-month weight (kg) (i.e., initial - 6 month weight). These changes were averaged for each group and compared between the two groups to assess whether there was a meaningful difference.

    12-month change: The absolute difference in the initial and 12-month weight (kg) (i.e., initial - 12 month weight).



Secondary Outcome Measures :
  1. Percent Excess Body Weight (%EBWL) Loss [ Time Frame: 1) 6 months post-procedure/sham and 2) 12 months post-procedure ]

    Percent excess body weight loss (% EBWL) is calculated by dividing the absolute weight loss divided by baseline excess weight and multiplying by 100% (i.e., excess weight / initial weight x 100%). Excess weight is defined as the difference between current weight and ideal weight.

    %EBWL was calculated for the following time points:

    1. 6 months: absolute weight loss was the difference from baseline to 6 months. %EBWL was averaged for each group and compared to assess whether there was a meaningful difference between the groups.
    2. 12 months: absolute weight loss was the difference from baseline to 12 months.

    Note, excess weight was determined from ideal body weights based on a BMI=25 kg/m2.


  2. Number of Patients With Weight Loss ≥5% [ Time Frame: 6 months post-procedure/sham ]
    Proportion of subjects who achieve ≥5% total body weight loss from baseline vs. those who do not

  3. 6 Month Change in Lipids [ Time Frame: 6 months post-procedure/sham ]
    6-month change (from baseline) in lipids for both groups. Unit of Measure: mg/dL

  4. 6 and 12 Month Change in Blood Pressure [ Time Frame: 6 months post-procedure/sham and 12 months post-procedure ]

    Change in absolute blood pressure levels from baseline to 6 months for both groups and baseline to 12 months for the initial treatment group.

    Unit of Measure: mmHg



Other Outcome Measures:
  1. Ghrelin Levels [ Time Frame: [Time Frame: 6-12 months] ]
    Unit of Measure: pg/mL

  2. Glucagon-like Peptide 1 Concentrations [ Time Frame: [Time Frame: 6-12 months] ]
    Changes in Glucagon-like peptide 1 concentrations Unit of Measure: pg/mL

  3. Oral Glucose Tolerance and Insulin Sensitivity [ Time Frame: [Time Frame: 6-12 months] ]
    Changes in OGTT and Insulin Sensitivity Unit of measure:milligrams/deciliter (mg/dL)

  4. Insulin Sensitivity [ Time Frame: [Time Frame: 6-12 months] ]
    Unit of measure: mg/min

  5. Changes in Mood (Depression/Anxiety) [ Time Frame: [Time Frame: 6-12 months] ]
    Unit of Measure: Beck Depression Index

  6. Change in Quality-of-life [ Time Frame: [Time Frame: 6-12 months] ]
    Change in the subdomains and overall Quality of Life Unit of Measure: IWQOL

  7. Change in Eating Behavior [ Time Frame: [Time Frame: 6-12 months] ]
    Unit of Measure: Eating Questionnaire Scores

  8. Change in Volume of Meal Test Consumed to Achieve Satiation: Satiation Drink Test. [ Time Frame: [Time Frame: 6-12 months] ]
    Change in satiety and other parameters associated with this test Unit of Measure: numerical scale from 0-5

  9. Results From Endoscopy [ Time Frame: 12 months ]
    Photos and clinical reports analyzed

  10. Gastric Motility/Emptying [ Time Frame: [Time Frame: 6-12 months] ]
    Unit of Measure: (t 1/2) in minutes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 66 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • BMI 35.0-50.0 kg/m2 at time of screening

    • Women of childbearing potential must agree to use at least one form of birth control (prescription hormonal contraceptives, diaphragm, IUD, condoms with or without spermicide, or voluntary abstinence) from time of study enrollment through study exit.
    • Willing and able to provide informed consent

Exclusion Criteria:

  • • Previous bariatric, gastric pancreatic, hepatic, and/or splenic surgery

    • History of duodenal or gastric ulcers or regularly taking medications (therapy >1 day per week) that can cause ulcers (e.g., non-steroidal anti-inflammatory drugs)
    • Prior radiation to the upper abdomen
    • Prior embolization to the stomach, spleen or liver
    • Portal venous hypertension
    • Active H. pylori infection
    • Uncontrolled hypertension (> 160/100 with or without medication).
    • Diabetes (determined by medical history, fasting blood glucose or results of an oral glucose tolerance test)
    • Serum triglyceride > 400 mg/dL at screening.
    • Class 4 or 5 surgical risk based on standard ASA criteria (Saklad M. Grading of patients for surgical procedures. Anesthesiol. 1941; 2:281-4).
    • Severe pulmonary or cardiovascular disease defined as a history or evidence of serious cardiovascular disease, including myocardial infarction, acute coronary syndrome, coronary revascularization, heart failure requiring medications, history of sudden cardiac death, or NYHA (New York Heart Association) class III or IV heart failure (defined below):

      • Class III: patients with marked limitation of activity; they are comfortable only at rest.
      • Class IV: patients who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest.
    • Coagulation disorders (platelets < 100,000, PT > 2 seconds above control or INR > 1.5 at screening).
    • Anemia (Hb < 10.0 g/dL) at screening.
    • Malignancy in the last 5 years (except for non-melanoma skin cancer).
    • Evidence of other significant organ system dysfunction (e.g. cirrhosis, renal failure)
    • Pregnant or lactating.
    • History of substance abuse in last 3 years.
    • Thyroid Stimulating Hormone (TSH) >2.0 x upper limit of normal at screening.
    • Taking prescription or over-the-counter medications for weight loss in the last 3 months before screening, or planning to participate in a commercial weight loss program in the next 5 years.
    • Taking diuretic medication for congestive heart failure or edema.
    • Evidence of significant mucosal inflammation, ulceration or ischemia detected on endoscopy, and those with unsuitable left gastric anatomy as judged by the study site physician will be excluded
    • Psychiatric illness that could affect compliance with the study, as judged by the site principle investigator.
    • Unable to complete screening requirements (compliance with visits and dietary record)
    • Taking medication once or more per week that causes weight gain (e.g. atypical antipsychotics, monoamine oxidase inhibitors, lithium, selected anticonvulsants, tamoxifen, glucocorticoids)
    • Chronic abdominal pain that would potentially complicate management.
    • Unstable weight (>3% change; self-reported) over the previous 2 months at time of screening.
    • Subjects whom the site investigator, research team, or the study medical monitor feel is not able to participate in the study for any reason, including poor general health or unable/unwilling to follow the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03185949


Locations
Layout table for location information
Czechia
OB klinika a.s., Pod Krejcárkem 975
Praha 3 - Žižkov, Czechia, 130 00
Sponsors and Collaborators
Endobar Solutions LLC
OB KLINIKA a.s. Pod Krejcárkem 975 Praha 3 - Žižkov Tel.: +420 255 725 110
Na Homolce Hospital
High Tech Med Consult Frimlova 1322/4e 15500 Prague 5 Czech Republic
Investigators
Layout table for investigator information
Principal Investigator: Martin Fried, MD OB klinika a.s., Prague, Czech Republic
Principal Investigator: Peter Neuzil, MD Na Homolce Hospital, Prague, Czech Republic
Principal Investigator: Vivek Reddy, MD Mount Sinai Medical Center, New York, NY, USA
  Study Documents (Full-Text)

Documents provided by Endobar Solutions LLC:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Endobar Solutions LLC
ClinicalTrials.gov Identifier: NCT03185949    
Other Study ID Numbers: ESC-14-001
First Posted: June 14, 2017    Key Record Dates
Results First Posted: September 28, 2022
Last Update Posted: September 28, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Endobar Solutions LLC:
Obesity
Embolization
Left Gastric Artery
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Obesity, Morbid
Overnutrition
Nutrition Disorders
Overweight
Body Weight